BIIB Biogen Inc.; UCB
Price Chart
Executive Summary
Biogen and UCB announced publication of full Phase 3 PHOENYCS GO results for dapirolizumab pegol (DZP) in The Lancet, showing a statistically significant improvement at Week 48 on the BICLA composite endpoint (50% vs 35%, p=0.011) in moderate-to-severe active SLE. However, the first key secondary endpoint at Week 24 was not met, disqualifying subsequent multiplicity-controlled comparisons, and the ongoing confirmatory PHOENYCS FLY trial is still recruiting with no regulatory submissions imminent. The data are incrementally positive but the path to approval remains contingent on a second confirmatory readout.
Actionable Insight
The data are directionally positive for DZP's approvability, but the non-multiplicity-controlled secondary endpoints and need for a second Phase 3 trial (PHOENYCS FLY)mean material regulatory catalyst is likely >2 years away. Monitor enrollment updates and eventual FLY topline; no near-term trading catalyst from this publication.
Key Facts
- Primary endpoint (BICLA response at Week 48) met: 50% for DZP + SOC vs 35% for placebo + SOC (p=0.011)
- First key secondary endpoint (BICLA response at Week 24) was not met, so subsequent outcomes were not controlled for multiplicity
- Serious TEAEs were lower with DZP + SOC (10.0%) vs placebo + SOC (14.8%); discontinuations low in both arms (4.7% vs 3.7%)
- PHOENYCS FLY confirmatory Phase 3 trial is currently recruiting; intended to support future regulatory filings
- DZP is an investigational Fc-free CD40L inhibitor, not approved by any health authority
- Biogen's market cap is $28.9B; UCB generated €7.7B revenue in 2025
Financial Impact
No financial terms disclosed; DZP is pre-commercial. A positive but incomplete Phase 3 readout does not change near-term revenue/EPS estimates for Biogen.
Risk Factors
- First key secondary endpoint (Week 24) failure weakens the overall statistical package and may concern regulators
- Confirmatory trial (PHOENYCS FLY) has not yet read out; development failure is still possible
- DZP is a collaboration asset — Biogen shares economics with UCB, limiting solo upside for BIIB
- No regulatory filings have been submitted or announced; timeline to potential approval is uncertain
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3304009 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 8, 2026
4d ago
|
ANALYST-UPGRADE
| $194.60 awaiting T+1 | awaiting T+1 | — | $200.05 (+2.80%) |
|
Jun 4, 2026
9d ago
|
Press Release
| $195.82 $195.30 | ▼ −0.27% | ▲ +2.33% | $200.05 (+2.16%) |
|
Jun 1, 2026
12d ago
|
Press Release
| $192.22 $188.66 | ▼ −1.85% | ▼ −2.00% | $200.05 (+4.08%) |
|
May 31, 2026
12d ago
|
ANALYST-UPGRADE
| $156.63 $154.99 | ▼ −1.05% | ▼ −1.18% | $200.05 (+27.72%) |
|
May 22, 2026
21d ago
|
ANALYST-UPGRADE
| $190.12 $187.84 | ▼ −1.20% | ▼ −0.81% | $200.05 (+5.22%) |
|
May 21, 2026
22d ago
|
Press Release
| $193.85 $193.07 | ▲ +0.40% | ▲ +0.99% | $200.05 (−3.20%) |
|
May 20, 2026
23d ago
|
ANALYST-UPGRADE
| $183.33 $185.18 | ▲ +1.01% | ▲ +1.66% | $200.05 (+9.12%) |
|
May 14, 2026
29d ago
|
ANALYST-UPGRADE
| $178.76 $180.47 | ▲ +0.96% | ▲ +0.18% | $200.05 (+11.91%) |
|
May 14, 2026
29d ago
|
Press Release
| $191.26 $192.32 | ▲ +0.55% | ▲ +1.78% | $200.05 (+4.60%) |
|
May 14, 2026
29d ago
|
8-K
| $191.26 $192.32 | ▲ +0.55% | ▲ +1.78% | $200.05 (+4.60%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access